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Introduction
Acute lymphoblastic leukemia (ALL) accounts for almost 30% of all 
childhood malignancies, i.e., ALL is the most frequent malignancy in 
pediatric population, and thus poses as the central problem of pediatric 
oncology. Approximately 80–85% of all childhood ALL cases originate 
from B-cell precursor (pB-ALL). Nowadays, as a result of long-standing 
global collaboration of pediatric oncologists, the first line treatment of 
childhood ALL assures 5-year event-free survival (EFS) for around 
85% of patients. However, still there are significant differences between 
risk groups and subtypes of childhood ALL in terms of refractoriness or 
relapse rate, which amounts 15–20% and remains the most common 
cause of the first-line treatment failure [1, 2, 3].
Despite the intensified second-line chemotherapy, stratified and combined 
with allogeneic hematopoietic stem cell transplantation (allo-HSCT) 
according to the recognized risk factors, only 30–50% of all children 
experiencing the first relapse of ALL obtain its second long-term complete 
remission (CR) [2]. The treatment results in children with refractory or 
multiple relapsed ALL are even much worse, and thus there is an urgent 
need to offer them new, more effective salvage therapeutic approaches 
integrating combined chemotherapy based on new formulations of existing 
agents and new agents along with immunotherapeutic and molecularly 
targeted therapeutic modalities [2, 4].
Among newer chemotherapeutic agents, clofarabine (2-chloro-2′-
fluoro-deoxy-9-b-d-arabinofuranosyladenine), a second generation 
purine nucleoside analog, takes a special place due its antitumor 
activity mechanism as well as its therapeutic and safety profile. 
Namelly, clofarabine inhibits DNA polymerase a and ribonucleotide 
reductase along with disruption of mitochondrial membrane integrity 
with subsequent release of proapoptotic factors leading to the death of 
both dividing and nondividing lymphocytes [5].
In pediatric and adult patients suffering from refractory and multiple 
relapsed acute leukemia, phase I and II studies with clofarabine as 
a single agent have shown its activity with an overall remission rate 
of 20% in pediatric patients and without dose-limiting neurotoxicity 
characteristic for the first-generation nucleoside analogs (fludarabine 
and cladribine) [6, 7].
Later, initially in preclinical experiments and then in phase I and II 
studies, a synergistic antileukemic effect of clofarabine in combination 
with cyclophosphamide and etoposide has been shown, which is 
based on clofarabine-mediated inhibition of the repair of damage to the 
DNA induced by the last two agents [8, 9]. From then several articles 
presenting results of combined chemotherapy consisted of clofarabine, 
etoposide, and cyclophosphamide (CEC) in children with refractory or 
multiple relapsed ALL have been published; however, presented results 
were ambiguous. Therefore, the Polish Pediatric Leukemia/Lymphoma 
Study Group (PPLLSG) decided to summarize its own experience in 
the field.
Patients and methods
This retrospective study evaluated eight pediatric patients (two females 
and six males) with advanced pB-ALL treated between 2015 and 2018 
in four centers of the PPLLSG by combined chemotherapy consisted 
of CEC (Tab. I).
Patients aged 4.5–16 years (median = 6 years) at the time of pB-ALL 
diagnosis and 5–18 years (median = 9 years) during the administration 
of CEC chemotherapy.
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Among the eight evaluated patients, one received CEC due to 
refractoriness to first line therapy (ALL IC-BFM 2009), three patients 
for first bone marrow relapse refractory to second line treatment 
(IntReALL 2010), three patients for second refractory relapse, and 
one patient for first bone marrow relapse that occurred 4 months after 
allo-HSCT given along with first line treatment of high-risk pB-ALL.
As an induction cycle, patients received clofarabine at a daily dose 
of 40 mg/m2 i.v. over 2 h for 5 days, followed by etoposide at a daily 
dose of 100 mg/m2 i.v. over 2 h for 5 days and cyclophosphamide at 
a daily dose of 440 mg/m2 i.v. over 1 h for 5 days.
Consolidation cycle consisted of the same agents as the ones used 
in induction cycle, which were administered for four consecutive 
days with the same daily doses given during induction. Prednisone 
was given a daily dose of 0.5 mg/kg for cytokine release syndrome 
prevention.
Of the eight evaluated children, five received 1–3 induction cycles of 
CEC therapy without any subsequent consolidation cycle, whereas 
the remaining three patients received 1–2 consolidation cycles alone.
All evaluated patients received anti-bacterial, anti-mycotic, and 
Pneumocystis jiroveci pneumonia prophylaxis.
Patients who achieved CR were given allo-HSCT if suitable donor 
was available and if there was no contraindications for allo-HSCT 
related to the clinical status of the patient.
Patient characteristics, administered treatment, and response to 
treatment are shown in table I.
Results and discussion
This is the first report on CEC chemotherapy results of children and 
adolescents with refractory/multiple relapsed ALL treated in centers 
of the PPLLSG. Admittedly the evaluated group of patients is small, 
however, it is homogeneous in terms of immunophenotype, because 
all patients suffered from pB-ALL.
Of the evaluated, as many as seven out of eight heavily pretreated 
patients with refractory pB-ALL achieved CR after CEC therapy, 
including three patients after one CEC induction cycle, one patient 
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after two, another one after three induction cycles, and finally one 
patient obtained CR after one consolidation cycle and another one 
after administration of two consolidation cycles. Only one patient with 
refractory second extramedullary relapse (in bone) failed to achieve 
CR after two consolidation cycles and died due to progression of the 
disease.
Thus, the response to CEC observed in the evaluated pediatric 
patients confirmed significant anti-leukemic capability of the regimen, 
which was even better than overall response rate of 42–69% (median 
= 55%) and CR rate of 18–52% (median = 38%) reported by other 
authors [9–13].
In addition, four patients underwent allo-HSCT for consolidating 
the obtained CR. However, despite the high rate of good early 
response, only one out of seven patients who achieved CR remains 
in CCR for 35 months. Among the remaining six patients, in two of 
them a subsequent relapse occurred despite CR consolidation with 
allo-HSCT (2.5 and 16 months after transplantation), four patients 
died due to infectious complications, including three patients after 
CEC regimen (at 2, 4.5, and 4.5 months of the regimen) during 
the course of prolonged myelosuppression, and one patient died 
35 days after matched unrelated donor HSCT as a result of CMV 
interstitial pneumonia with respiratory insufficiency and multi-organ 
failure (MOF). Only two patients are still alive, including one in CCR 
for 38 months from CEC and the second one for 42 months from 
CEC now in fourth CR achieved with CAR-T cells after post-CEC and 
post allo-HSCT relapse. Thus, in our patients the long-term results 
were much poorer than those reported by Liu et al. [13] (EFS 38.5% 
and OS 51.3% at 12 months) and by Locatelli et al. [10] (OS 33% at 
18 months); however, other authors also found relapse/progression 
and infections occurring in course of prolonged neutropenia as major 
causes of treatment failures [9–13]. In addition, the IntReALL Group 
initially aimed at comparing the CEC regimen with the established 
ALL-REZ BFM regimen F1 and F2 for induction therapy of children 
with high risk (HR) relapse of ALL. A pilot study of the United Kingdom 
Group started in 2010 to confirm the feasibility of the regimen in the 
intended indication, however, revealed inferior EFS rates compared 
to the historical controls [14].
In contrast to deep and long-lasting myelosuppression with 
subsequent severe infections observed both in the evaluated 
patients and in patients reported by some other authors [8, 9, 11], the 
severe toxicity of organs, in particular, severe hepatoxicity, including 
sinusoidal obstruction syndrome (SOS) [8, 9], was not observed and 
none of the evaluated children died due to CEC regimen-related 
organ toxicity. Similar observations have been made by Locatelli et 
al. [10] and Miano et al. [12].
Conclusions
In the evaluated group of pediatric patients with refractory or multiple 
relapsed pB-ALL the regimen consisted of CEC demonstrated 
significant early anti-leukemic activity in terms of obtained CR rate, 
but an incidence of treatment failure due to infectious complications 
as well as an incidence of subsequent relapse/progression, including 
post-transplant relapse, was very high and indicates, respectively, 
on deep, prolonged myelosuppression and low quality of CR after 
CEC regimen alone. Therefore, to achieve a significant improvement 
of long-term results in children with resistant and multiple relapsed 
pB-ALL, implementation and integration of novel treatment 
approaches are indispensable, including immunotherapy with 
CAR-T cells, blinatumomab or inotuzumab along with personalized, 
molecularly targeted drugs, and a consolidative allo-HSCT in selected 
patients [4, 15].
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